The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The medication will be sold under the brand name Journavx for $15.50 per pill, according to Vertex Pharmaceuticals, the company that developed the new drug. The FDA's sign-off on the medication ...

Journavx was found to be as similarly effective as hydrocodone, an opioid pain medication, for reducing acute pain, with the added benefit of being a non-opioid and non-addictive drug.

Vertex Pharmaceuticals announced that Journavx will be priced at $15.50 per pill.The FDA-approved medication, available as a 50-milligram prescription tablet taken every 12 hours, offers a non ...

The FDA on Thursday approved Vertex Pharmaceuticals' Journavx to treat moderate to severe acute pain in adults. Acute pain is short-term pain often caused by surgery, accident or injury.

The FDA's approval process for Journavx included an evaluation of its safety and efficacy. Clinical trials demonstrated that the drug is effective in managing acute pain without the adverse ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain ... drug pipeline that involves winning FDA approval for multiple drugs across several ...

Journavx became the first drug in a new class of pain management medications to be FDA approved. The treatment showed statistically significant superiority to placebo in trials. Perspective from ...

FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential' A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous By ...

Among the patients who received Journavx in the clinical trials was a 50-year-old woman from the Atlanta area. She had a nose job in October 2023 and began taking the pill immediately afterward in ...